Cancer Trials Ireland > Cancer Trials > Head & Neck

DSSG Group: Head & Neck

MK-3475-689

Name No. For Patients with Purpose
MK-3475-689 19-39

Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

To assess major pathological response and event free survival
when pembrolizumab is given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) compared to radiotherapy (with or without cisplatin) given after surgery alone.

CompARE

Name No. For Patients with Purpose
CompARE 17-14

intermediate and high-risk oropharyngeal
cancer

To examine the outcomes of alternative treatments aiming to improve overall survival time in intermediate and high-risk oropharyngeal cancer and to compare Quality of Life (QoL), toxicity outcomes and swallowing function of these alternative treatments

PRESERVE

Name No. For Patients with Purpose
PRESERVE 20-04

Resected oral cavity squamous cell carcinoma

The purpose of this study is to compare oncologic outcomes, functional outcomes, and quality of life (QoL) in patients treated with standard radiotherapy volumes vs. radiotherapy to the primary site and pathologically involved hemi-neck only, omitting radiation to the pN0 hemi-neck(s).

MK-3475-630/KEYNOTE-630

Name No. For Patients with Purpose
MK-3475-630/KEYNOTE-630 CTRIAL-IE 20-08

Melanoma

This is a randomized study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).